- Responsiveness of epigenetic aging biomarkers to longevity interventions in humans
Nature Medicine, Published online: 21 August 2026; doi:10.1038/s41591-026-04562-9The responsiveness of 16 different epigenetic aging clocks to a broad array of pharmacological and lifestyle interventions in humans was assessed across 51 different longitudinal studies, providing insights into the potential of aging clocks to serve as reliable aging biomarkers.
- Dysregulated adult hippocampal neurogenesis in major depressive disorders
Nature Medicine, Published online: 21 August 2026; doi:10.1038/s41591-026-04571-8The largest multiomic atlas of the adult human hippocampus identifies disrupted neurogenesis, gene regulation and neural circuits in major depressive disorder, revealing molecular pathways and potential therapeutic targets related to stress, cellular aging and neuroplasticity.
- Can traditional medicines go mainstream?
Nature Medicine, Published online: 21 August 2026; doi:10.1038/s41591-026-04588-zTraditional medicine is already used by billions worldwide. Researchers, regulators and the World Health Organization (WHO) are now working to generate acceptable evidence, win regulatory acceptance, and integrate traditional medicines into modern clinical care.
- Putting epigenetic aging clocks on trial
Nature Medicine, Published online: 21 August 2026; doi:10.1038/s41591-026-04524-1A new study offers the first systematic test of whether DNA methylation clocks behave the way a surrogate endpoint for aging should, responding to genuine clinical benefit and remaining stable when there is none.
- The trials of translating psilocybin treatment from research to practice
Nature Medicine, Published online: 21 August 2026; doi:10.1038/s41591-026-04597-yA feasibility trial delivering psilocybin-assisted therapy for treatment-resistant depression within the UK health service reports encouraging adherence and safety — it opens future questions about who is reached, where treatment happens and what standards will be needed to sustain it.
- Intercepting pancreatic cancer with a vaccine
Nature Medicine, Published online: 20 August 2026; doi:10.1038/d41591-026-00041-3An ‘off-the-shelf’ vaccine that targets mutant KRAS can safely and durably activate T cell responses in healthy people at high risk of developing pancreatic cancer, according to a phase 1 study.
- County surveillance failed to detect that measles transmission reached epidemic threshold in schools
Nature Medicine, Published online: 20 August 2026; doi:10.1038/s41591-026-04612-2A nationwide analysis of measles vaccination records from more than 50,000 US schools shows that measles transmission risk crossed the threshold that can lead to epidemics at the school level in the 2–3 years before the 2025–2026 outbreaks, whereas county-level estimates always remained below that threshold.
- Waking from the nightmare of PTSD
Nature Medicine, Published online: 19 August 2026; doi:10.1038/s41591-026-04586-1Dronabinol, the pharmaceutical form of Δ9-tetrahydrocannabinol, shows promise in the treatment of nightmares related to post-traumatic stress disorder (PTSD), but additional studies are needed to confirm safety and efficacy.